Regarding Forward-Looking Statements

This presentation includes forward-looking statements. We make forward-looking statements, as defined by the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, and in some cases, you can identify these statements by forward-looking words such as “if,” “shall,” “may,” “might,” “will likely result,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “goal,” “objective,” “predict,” “potential” or “continue,” or the negative of these terms and other comparable terminology. These include statements regarding: our ability to leverage our technology platform in the development of our lead and potential pipeline product candidates; our ability to design and conduct development activities and studies and clinical trials for our lead and potential pipeline product candidates; the potential timing and results of any such clinical trials we may conduct; our ability to obtain regulatory approvals in order to market any planned products; our ability to achieve financial projections; and our ability to achieve milestones. The forward-looking statements in this presentation are based on management’s current expectations, estimates, forecasts and projections about the Company and its business, all of which could prove to be wrong. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for current and future fiscal years could differ materially from the Company’s current expectations. Factors that could cause the Company’s results to differ materially from those expressed in forward-looking statements include, without limitation, the following risks: we have estimated that we will have sufficient cash to operate our business through May 2015, and we may not be able to obtain sufficient financing and/or establish necessary relationships with third parties to continue to pursue our business plan; any stockholder dilution that may result from future capital raising efforts; our ability to raise capital on terms favorable to the Company and its current stockholders; any development activities or clinical trials we may conduct which may not produce favorable results; regulatory agencies may require that we undertake additional or more costly studies or clinical trials than we presently anticipate; we may never gain regulatory approval for any of our product candidates; we may not be able to protect our intellectual property rights; the intellectual property of others and any asserted claims of infringement; general business and economic conditions may limit our ability to obtain necessary capital; the consequences of competitive factors in the industry in which we operate may restrict the success of any product candidate we are able to commercialize, and we may not be able to attract or retain key personnel. More detailed information about the Company and the risk factors that may affect the realization of any forward-looking statements shall be found in our filings with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Such documents may be read free of charge on the SEC’s internet site at http://www.sec.gov. You are cautioned not to place undue reliance on any forward-looking statements we make in this presentation. Given these risks and uncertainties, all such statements are qualified in their entirety by this cautionary statement. All forward-looking statements speak only as of the date hereof, and we undertake no obligation to revise or update any forward-looking statement to reflect events or circumstances after the date hereof, except as otherwise required by law.
Overview

Cell MedX Corp. (The “Company”) is an early development stage company publicly traded on the OTC Markets under the symbol CMXC.

Cell MedX is focused on the development and commercialization of innovative therapeutic products for the treatment of diabetes and related complications.

- Currently there are 382 million people living with diabetes worldwide.
- This number is likely to grow to nearly 600 million within a generation.

Chances are, this means you, or someone you know, needs help. Today.
About Us

- Cell MedX is expanding on the traditional pharmaceutical healthcare model of managing chronic illnesses like diabetes, through the introduction of electro-chemical therapies.

- At Cell MedX we are developing devices that treat chronic and acute conditions for both clinical and self management care of diabetes.

- Cell MedX is establishing a potentially all-new category of diabetes care.
Diabetic Marketplace

Diabetes - one of the world’s oldest diseases. Previously considered a disease of the affluent, diabetes is now considered an epidemic.

- Latest estimate: 382 million people with diabetes worldwide.
- By 2035, 592 million people (one person in ten) will have the disease.
- 316 million people are currently at high risk of developing type 2 diabetes.
Diabetes Economic Impact

Diabetes imposes a large economic burden on national healthcare systems

- Expenditures on treatment of diabetes accounted for 11.6% of the total healthcare expenditure in the world in 2010.

- About 95% of countries will spend 5% or more, with about 80% of the countries spending between 5% and 13% of their total healthcare dollars on diabetes.

- Global health expenditures to prevent and treat diabetes (and complications) totaled $376 billion in 2010.

- By 2030, this will exceed $490 billion.
Cell MedX Proposition

- The application of electromagnetic forces to human tissues to effect change has been around since the 19th century.
- Today we see a resurgence in legitimate, peer-reviewed biologic research, focused on the concept of molecular bioelectricity and its role in cell-to-cell signaling.
- Ion flows and trans-membrane gradients produced by ion channels and pumps are key regulators of cell proliferation, migration, and differentiation.
- Now, instructive roles for bioelectrical gradients in embryogenesis, regeneration, and neoplasm are being revealed.
- There is speculation of “cracking the bioelectric code” with the same excitement that portended the cracking of the genetic code.

There has been no new major breakthroughs in the treatment of diabetes since the discovery of insulin over 90 years ago.
Current Chemical Therapies

In the absence of a cure, the goal of diabetes management is to alter the natural course of the disease by reducing the likelihood of complications by eliminating the wide fluctuations in blood sugar that define the disease.

The following diabetic conditions are difficult and sometimes impossible to manage with chemical-only methods (pharmaceuticals):

- Insulin resistance (a lifelong issue)
- Cell Communication
- Aggressive Medication in Type 2 patients
- Painful Diabetic Neuropathies
- Wound Healing
Consider This:

- Microcurrent delivery devices used for the treatment of diabetic neuropathy and poor wound healing in diabetics have been in the marketplace for decades.

  **The e-balance Technology is different.**

- Other devices offer a limited utility and are not designed to treat diabetes at its core — the underlying metabolic disorder that leads to hyperglycemia and its sequelae.

- Devices incorporating the e-balance Technology will aim to effect changes much further “upstream” in the pathophysiology or natural history of diabetes.
An Undervalued Opportunity?

- Energy medicine appears to be a significantly undervalued opportunity on the health care landscape.
- Technology-enabled self-care models have shown reduced complications and improved quality of life in T1DM.
- Replicating these results in T2DM has been challenging, reflecting the heterogeneous nature of the disease and that it changes with age and other factors.
- Molecular bioelectricity and its role in cell-to-cell signaling and epigenetics (altering cell behavior without altering genes) provides a new pathway to discovery of technologies that can counteract the effects of many diseases.
Introducing e-balance

A New Path to Diabetic Freedom

• Cell MedX is developing a radically different and very promising device that is distinctly unlike the approaches currently in use or in the treatment pipeline and, if proven through diligent research and development, could open a new category of diabetes care.

• The e-balance Technology is intended to expand the traditional healthcare model of diabetes management by enabling patients to manage their symptoms using a biosignal generating device that is simple to use, causes no discomfort, and can easily be incorporated into any lifestyle.

• The e-balance device aims to focus on overall diabetes management, including reductions in average blood sugar (HbA1C) as well as other markers that denote the degree and quality of blood sugar control. Measures that track complications of the disease will also be in focus.
e-balance:
A planned tablet-sized homecare device with proprietary downloadable software and specialized treatment accessories.
e-balance Benefits

The technology aims to offer;

• Ease of use.
• Administration by paramedical personnel or by patients at home.
• Expansion of the practitioners clinical capability.
• Enhancement to the total efficacy of clinical efforts.
• An alternative therapy and as an adjunct to conventional methods.
• Elimination or reduction to the need for addictive medication in chronic pain and stress syndrome.
• Limited use of polypharmacy effects that are not well tolerated.
• Application on a scheduled basis or as needed.
• Cumulative and long term effect as healing ensues.
• Cost effective, durable and used for years.
Highlights

• **Investment Theme:** Potential high margin (~biochemistry and biophysics) product entering large growing market (2015) with lower (device) capital requirements.

• **Significant Opportunity:** Growing multi-billion dollar market needs better solutions for chronic diabetes care management.

• **First Planned Product:** Consumer use microcurrent technology (MET).

• **Ideal Product Profile:** Electro-Therapy Device, safe, easy to use, limited complications.

• **Unique Solution:** Undervalued sector, valid science, rapidly growing field.

• **2015 Activities:** Scale-up; biocompatibility, ongoing trials, manufacturing.

• **Pipeline:** Large potential in growing market, consumers, clinicians, long term care.
  - Government Funding: past prequalification; significant fresh opportunities.

• **OTC:** CMXC
Company Profile

Cell MedX Corp.
74 N. Pecos, Suite D
Henderson, NV 89074
T: 310-508-9398
E: info@cellmedx.com

OTC: CMXC
CUSIP No.: 15115X 107
ISIN No., US15115X1072
Incorporated in Nevada (03/19/2010)
Fiscal Year End: May 31st
Shares Outstanding: 31MM (10/06/2014)

Auditor
Dale Matheson Carr-Hilton Labonte LLP
Chartered Accountants
1500/1700 - 1140 West Pender St.
Vancouver, BC V6E 4G1

Transfer Agent
Pacific Stock Transfer
4045 South Spencer Street, Suite 403
T: (702) 361-3033

Investor Relations
Cell MedX Investor Relations
T: 310-508-9398
E: investors@cellmedx.com

Legal Counsel
O’Neill Law Corporation
Suite 704, 595 Howe Street,
Vancouver, BC V6C 2T5

www.cellmedx.com
Thank you

OTC: CMXC